Journal
NATURE CELL BIOLOGY
Volume 23, Issue 7, Pages 682-683Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41556-021-00712-y
Keywords
-
Categories
Ask authors/readers for more resources
A new study has shown that the SARS-CoV-2 nucleocapsid protein can suppress the antiviral response by directly interacting with the signalling adaptor protein MAVS. Targeting this pathway could be a promising therapeutic strategy to enhance immunity against COVID-19.
A new study shows that the SARS-CoV-2 nucleocapsid protein represses the antiviral type I interferon response through direct interaction with the signalling adaptor protein MAVS. Targeting this process might be a useful therapeutic strategy to boost immunity against COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
